ClinicalTrials.gg

Retinal Vein Occlusion clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 289 studies for Retinal Vein Occlusion across more than 10 countries. 32 are recruiting or about to start. 156 of them are mainly about Retinal Vein Occlusion (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
171
Status unknown
47
Terminated
24
Recruiting
18
Not yet recruiting
12
Active, not recruiting
10

Phase

Phase 3
58
Phase 2
56
Phase 4
40
Phase 1
34
Early Phase 1
4

Where

United States
106
China
36
France
30
Germany
26
United Kingdom
22
Canada
22

Who develops what

Add Retinal Vein Occlusion to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Changchun GeneScience Pharmaceutical and Merck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, limited
Evidence
  • NCT07205887 · Merck & Co., Inc · Phase 2 · live · background · “Aflibercept 2.0 mg” · registered Sep 2025
  • NCT04740931 · Hoffmann-La Roche · Phase 3 · background · “Aflibercept” · registered Feb 2021
  • NCT04740905 · Hoffmann-La Roche · Phase 3 · background · “Aflibercept” · registered Feb 2021
  • NCT04592419 · Kodiak Sciences Inc · Phase 3 · comparator · “Aflibercept” · registered Oct 2020
  • NCT03810313 · Novartis · Phase 3 · comparator · “Aflibercept 2 mg” · registered Jan 2019
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others11 study
proxymetacaineRecent, limited
Evidence
  • NCT07456826 · Harrow Inc · Phase 4 · live · comparator · “Proparacaine Hydrochloride Ophthalmic Solution 0.5%” · registered Feb 2026
—11 study
LidocaineRecent, limited
Evidence
  • NCT07456826 · Harrow Inc · Phase 4 · live · comparator · “Lidocaine Hydrochloride Injection 2%” · registered Feb 2026
Keenova Therapeutics plc17% of its industry studiesUS: off-patent, 62 generics marketed11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jul 2027 est.SMO1 · SANGMYUNG innovation · Phase 3 named, not the main aimNCT07708142 Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema — primary endpoint: Best corrected visual acuity (BCVA) at Month 2 · 312 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Retinal Vein Occlusion studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 1 open · Local anesthetics 1 open · Corticosteroids 28

Coming up

11studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (22%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
101 (6%)1 (6%)
1815 (83%)15 (83%)
3016 (89%)16 (89%)
4016 (89%)16 (89%)
5018 (100%)18 (100%)
6518 (100%)18 (100%)
7518 (100%)18 (100%)
8516 (89%)16 (89%)

Across all 289 studies, recruiting or not: 3% stop at 75 or younger and 1% at 65; 10% take children; 0% are for women only and 0% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Retinal Vein Occlusion studies take

Of 19 phase 4 interventional studies under Retinal Vein Occlusion, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 222 mo14–29 · 14 studies——
Phase 326 mo17–41 · 18 studies——
Phase 435 mo19–47 · 19 studies——
Interventional, no phase37 mo11–… · 22 studies——
Observational52 mo18–69 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 289. Browse all 289 → or search them.